Up-to-date review on concomitant mitral transcatheter edge-to-edge repair and left atrial appendage occlusion.

IF 1 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Graeme Prosperi-Porta, Abdullah Al-Abcha, Trevor Simard, Benjamin Hibbert, Omar Abdel-Razek
{"title":"Up-to-date review on concomitant mitral transcatheter edge-to-edge repair and left atrial appendage occlusion.","authors":"Graeme Prosperi-Porta, Abdullah Al-Abcha, Trevor Simard, Benjamin Hibbert, Omar Abdel-Razek","doi":"10.1080/14796678.2025.2543184","DOIUrl":null,"url":null,"abstract":"<p><p>In patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER), atrial fibrillation is a common comorbidity. While oral anticoagulation is the mainstay of stroke prevention therapy in most patients with atrial fibrillation, patients undergoing M-TEER might have a unique opportunity to undergo concomitant left atrial appendage occlusion (LAAO). LAAO is an alternative to oral anticoagulation that reduces the long-term risk of stroke and major bleeding, but it comes with upfront peri-procedural risk. M-TEER and LAAO share numerous procedural characteristics including large-bore venous access, transseptal puncture, general anesthesia, and real-time imaging of the left atrium with echocardiography. Therefore, performing concomitant LAAO at the time of M-TEER might be an attractive option for patients to lessen the cumulative peri-procedural risk, repeated anesthetic, and hospital visits from separate procedures. With rapidly evolving device technologies and an increasing evidence base for LAAO use, there is still limited data evaluating the safety and feasibility of concomitant M-TEER and LAAO. This up-to-date narrative review on concomitant M-TEER and LAAO aims to summarize the current body of literature, review practical procedural considerations, and review the unmet research questions limiting the widespread adoption of this concomitant intervention.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-9"},"PeriodicalIF":1.0000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2025.2543184","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

In patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER), atrial fibrillation is a common comorbidity. While oral anticoagulation is the mainstay of stroke prevention therapy in most patients with atrial fibrillation, patients undergoing M-TEER might have a unique opportunity to undergo concomitant left atrial appendage occlusion (LAAO). LAAO is an alternative to oral anticoagulation that reduces the long-term risk of stroke and major bleeding, but it comes with upfront peri-procedural risk. M-TEER and LAAO share numerous procedural characteristics including large-bore venous access, transseptal puncture, general anesthesia, and real-time imaging of the left atrium with echocardiography. Therefore, performing concomitant LAAO at the time of M-TEER might be an attractive option for patients to lessen the cumulative peri-procedural risk, repeated anesthetic, and hospital visits from separate procedures. With rapidly evolving device technologies and an increasing evidence base for LAAO use, there is still limited data evaluating the safety and feasibility of concomitant M-TEER and LAAO. This up-to-date narrative review on concomitant M-TEER and LAAO aims to summarize the current body of literature, review practical procedural considerations, and review the unmet research questions limiting the widespread adoption of this concomitant intervention.

二尖瓣经导管边缘对边缘修复和左心耳闭塞术的最新研究进展。
在接受二尖瓣经导管边缘到边缘修复(M-TEER)的患者中,心房颤动是一种常见的合并症。虽然口服抗凝是大多数房颤患者卒中预防治疗的主要手段,但接受M-TEER治疗的患者可能有独特的机会接受合并左心耳闭塞(LAAO)。LAAO是口服抗凝剂的一种替代方案,可降低中风和大出血的长期风险,但它具有前期围手术期风险。M-TEER和LAAO有许多相同的手术特点,包括大口径静脉通路、经间隔穿刺、全身麻醉和超声心动图实时成像左心房。因此,在M-TEER时进行合并LAAO可能是一个有吸引力的选择,可以减少累积的围手术期风险、重复麻醉和单独手术的住院次数。随着设备技术的快速发展和LAAO使用的证据基础的增加,评估M-TEER和LAAO联合使用的安全性和可行性的数据仍然有限。这篇最新的关于M-TEER和LAAO联合干预的叙述性综述旨在总结当前的文献,回顾实际的程序考虑,并回顾限制这种联合干预广泛采用的未满足的研究问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future cardiology
Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.80
自引率
5.90%
发文量
87
期刊介绍: Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信